Innate Pharma releases its financial calendar for 2020
December 4, 2019Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) today released its 2020 financial calendar: March 10, 2020: Publication of 2019 financial statements, with...Innate Pharma certified as a Great Place to Work®
December 3, 2019Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) today announced its certification as a great work place by the independent institute, Great Place to Work®, a global...Innate Pharma third quarter 2019 report
November 13, 2019Cash, cash equivalents and financial assets of the Company amounted to €215.2 million* $79.1 million (€71.4 million**) in gross proceeds from our IPO on the Nasdaq and Global Offering Monalizumab to...Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting
November 7, 2019Long-term data analysis will expand on previously reported efficacy results from Lumoxiti Phase III trial Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the...Number of shares and voting rights of Innate Pharma as at November 1, 2019
November 6, 2019Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...Innate Pharma announces preclinical data presentations at SITC 2019
November 6, 2019Preclinical data showcases advancement of its immuno-oncology portfolio across the Company’s three strategic pillars: immune checkpoint inhibitors, tumor antigen targeting and tumor micro-environment...
